| # | Title | Journal | Year | Citations |
|---|
| 1 | Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer | Journal of Nuclear Medicine | 2016 | 155 |
| 2 | Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer | Journal of Nuclear Medicine | 2015 | 95 |
| 3 | Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging | Journal of Nuclear Medicine | 2018 | 70 |
| 4 | Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program | Oncologist | 2018 | 60 |
| 5 | Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management | Journal of Nuclear Medicine | 2020 | 52 |
| 6 | Initial experience with a SiPM-based PET/CT scanner: influence of acquisition time on image quality | EJNMMI Physics | 2018 | 47 |
| 7 | Biodistribution of the 18F-FPPRGD2 PET radiopharmaceutical in cancer patients: an atlas of SUV measurements | European Journal of Nuclear Medicine and Molecular Imaging | 2015 | 43 |
| 8 | Bombesin-Targeted PET of Prostate Cancer | Journal of Nuclear Medicine | 2016 | 43 |
| 9 | Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors | European Journal of Nuclear Medicine and Molecular Imaging | 2019 | 43 |
| 10 | Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer | Journal of Nuclear Medicine | 2020 | 42 |
| 11 | Comparison of 3 Interpretation Criteria for 68Ga-PSMA11 PET Based on Inter- and Intrareader Agreement | Journal of Nuclear Medicine | 2020 | 40 |
| 12 | PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer | Journal of Nuclear Medicine | 2021 | 37 |
| 13 | New PET technologies – embracing progress and pushing the limits | European Journal of Nuclear Medicine and Molecular Imaging | 2021 | 35 |
| 14 | Fusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell types | European Journal of Nuclear Medicine and Molecular Imaging | 2015 | 30 |
| 15 | Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer | Journal of Nuclear Medicine | 2016 | 30 |
| 16 | Radioactive iodine in differentiated thyroid cancer: a national database perspective | Endocrine-Related Cancer | 2019 | 30 |
| 17 | Improvements in PET Image Quality in Time of Flight (TOF) Simultaneous PET/MRI | Molecular Imaging and Biology | 2016 | 26 |
| 18 | Pilot prospective evaluation of 18F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer | European Journal of Nuclear Medicine and Molecular Imaging | 2016 | 25 |
| 19 | Will GRPR Compete with PSMA as a Target in Prostate Cancer? | Journal of Nuclear Medicine | 2017 | 25 |
| 20 | Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging | Nanotheranostics | 2022 | 25 |
| 21 | Deep learning detection of prostate cancer recurrence with 18F-FACBC (fluciclovine, Axumin®) positron emission tomography | European Journal of Nuclear Medicine and Molecular Imaging | 2020 | 24 |
| 22 | Clinical Evaluation of 68Ga-PSMA-II and 68Ga-RM2 PET Images Reconstructed With an Improved Scatter Correction Algorithm | American Journal of Roentgenology | 2018 | 22 |
| 23 | Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy | European Journal of Nuclear Medicine and Molecular Imaging | 2020 | 21 |
| 24 | PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature | Cancers | 2022 | 21 |
| 25 | Clinical evaluation of TOF versus non-TOF on PET artifacts in simultaneous PET/MR: a dual centre experience | European Journal of Nuclear Medicine and Molecular Imaging | 2017 | 20 |
| 26 | Radiolabeled prostate-specific membrane antigen small-molecule inhibitors | Quarterly Journal of Nuclear Medicine and Molecular Imaging | 2017 | 19 |
| 27 | Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas | European Journal of Nuclear Medicine and Molecular Imaging | 2021 | 17 |
| 28 | Semiquantitative Analysis of the Biodistribution of the Combined 18F-NaF and 18F-FDG Administration for PET/CT Imaging | Journal of Nuclear Medicine | 2015 | 15 |
| 29 | Performance Comparison of Individual and Ensemble CNN Models for the Classification of Brain 18F-FDG-PET Scans | Journal of Digital Imaging | 2020 | 15 |
| 30 | Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[18F] F and [18F]FDG: a Focus on Skeletal Lesions | Molecular Imaging and Biology | 2020 | 14 |
| 31 | Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-d-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy | Molecular Imaging and Biology | 2021 | 12 |
| 32 | 18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer | European Journal of Nuclear Medicine and Molecular Imaging | 2019 | 11 |
| 33 | Will FAPI PET/CT Replace FDG PET/CT in the Next Decade? Counterpoint—No, Not So Fast! | American Journal of Roentgenology | 2021 | 11 |
| 34 | To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy | Journal of Nuclear Medicine | 2021 | 11 |
| 35 | Imaging of Prostate Cancer Using Gallium-68–Labeled Bombesin | PET Clinics | 2017 | 10 |
| 36 | Human biodistribution and radiation dosimetry of [18F]DASA-23, a PET probe targeting pyruvate kinase M2 | European Journal of Nuclear Medicine and Molecular Imaging | 2020 | 10 |
| 37 | Pilot-phase PET/CT study targeting integrin αvβ6 in pancreatic cancer patients using the cystine-knot peptide–based 18F-FP-R01-MG-F2 | European Journal of Nuclear Medicine and Molecular Imaging | 2021 | 10 |
| 38 | High quality imaging and dosimetry for yttrium-90 (90Y) liver radioembolization using a SiPM-based PET/CT scanner | European Journal of Nuclear Medicine and Molecular Imaging | 2021 | 9 |
| 39 | 18F-FDG PET/CT for Evaluation of Post-Transplant Lymphoproliferative Disorder (PTLD) | Seminars in Nuclear Medicine | 2021 | 9 |
| 40 | A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma | Clinical Cancer Research | 2021 | 9 |
| 41 | A Prospective, Matched Comparison Study of SUV Measurements From Time-of-Flight Versus Non–Time-of-Flight PET/CT Scanners | Clinical Nuclear Medicine | 2016 | 7 |
| 42 | The Role of PET/CT in the Imaging of Pancreatic Neoplasms | Seminars in Ultrasound, CT and MRI | 2019 | 7 |
| 43 | Malignant Cutaneous Melanoma: Updates in PET Imaging | Current Radiopharmaceuticals | 2020 | 7 |
| 44 | Role of CT Density in PET/CT-Based Assessment of Lymphoma | Molecular Imaging and Biology | 2018 | 6 |
| 45 | Prostate cancer: Molecular imaging and MRI | European Journal of Radiology | 2021 | 6 |
| 46 | Imaging gastrin-releasing peptide receptors (GRPRs) in prostate cancer | Clinical and Translational Imaging | 2019 | 5 |
| 47 | Optimization of 89Zr PET Imaging for Improved Multisite Quantification and Lesion Detection Using an Anthropomorphic Phantom | Journal of Nuclear Medicine Technology | 2020 | 5 |
| 48 | Clinical application of Fluciclovine PET, choline PET and gastrin-releasing polypeptide receptor (bombesin) targeting PET in prostate cancer | Current Opinion in Urology | 2020 | 5 |
| 49 | The Clinical Utility of 18F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval | Molecular Imaging and Biology | 2021 | 5 |
| 50 | Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab | JAMA Neurology | 2021 | 5 |
